Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Silica-lipid hybrid (SLH) microcapsules : a novel oral delivery system for poorly soluble drugs. / Tan, Angel; Simovic, Spomenka; Davey, Andrew K; Rades, Thomas; Prestidge, Clive A.

In: Journal of controlled release : official journal of the Controlled Release Society, Vol. 134, No. 1, 2009, p. 62-70.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Tan, A, Simovic, S, Davey, AK, Rades, T & Prestidge, CA 2009, 'Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs', Journal of controlled release : official journal of the Controlled Release Society, vol. 134, no. 1, pp. 62-70. https://doi.org/10.1016/j.jconrel.2008.10.014

APA

Tan, A., Simovic, S., Davey, A. K., Rades, T., & Prestidge, C. A. (2009). Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs. Journal of controlled release : official journal of the Controlled Release Society, 134(1), 62-70. https://doi.org/10.1016/j.jconrel.2008.10.014

Vancouver

Tan A, Simovic S, Davey AK, Rades T, Prestidge CA. Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs. Journal of controlled release : official journal of the Controlled Release Society. 2009;134(1):62-70. https://doi.org/10.1016/j.jconrel.2008.10.014

Author

Tan, Angel ; Simovic, Spomenka ; Davey, Andrew K ; Rades, Thomas ; Prestidge, Clive A. / Silica-lipid hybrid (SLH) microcapsules : a novel oral delivery system for poorly soluble drugs. In: Journal of controlled release : official journal of the Controlled Release Society. 2009 ; Vol. 134, No. 1. pp. 62-70.

Bibtex

@article{66cda8ad0c604ce3958fa70b6589b9b0,
title = "Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs",
abstract = "A silica-lipid hybrid (SLH) microcapsule system for oral delivery of poorly water-soluble drugs is reported for the first time. For the model drug celecoxib (CEL), SLH microcapsules composed of medium-chain triglycerides, lecithin and silica nanoparticles; with an internal porous matrix structure, were shown to offer several physicochemical and biopharmaceutical advantages in comparison with unmodified drug, lipid emulsion, dry emulsion and the commercial product, Celebrex. DSC and XRD analyses confirmed non-crystalline CEL in SLH microcapsules and verified medium term physical stability. Dissolution under sink conditions revealed a 2- to 5-fold increase in dissolution efficiencies (%DE) and significantly reduced t(50%) (> or =50-fold) for CEL formulated as SLH microcapsules. Orally dosed in vivo studies in rats demonstrated superior pharmacokinetics for SLH microcapsules. Specifically, the fasted-state bioavailability (F) was statistically higher (p",
author = "Angel Tan and Spomenka Simovic and Davey, {Andrew K} and Thomas Rades and Prestidge, {Clive A}",
year = "2009",
doi = "10.1016/j.jconrel.2008.10.014",
language = "English",
volume = "134",
pages = "62--70",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "1",

}

RIS

TY - JOUR

T1 - Silica-lipid hybrid (SLH) microcapsules

T2 - a novel oral delivery system for poorly soluble drugs

AU - Tan, Angel

AU - Simovic, Spomenka

AU - Davey, Andrew K

AU - Rades, Thomas

AU - Prestidge, Clive A

PY - 2009

Y1 - 2009

N2 - A silica-lipid hybrid (SLH) microcapsule system for oral delivery of poorly water-soluble drugs is reported for the first time. For the model drug celecoxib (CEL), SLH microcapsules composed of medium-chain triglycerides, lecithin and silica nanoparticles; with an internal porous matrix structure, were shown to offer several physicochemical and biopharmaceutical advantages in comparison with unmodified drug, lipid emulsion, dry emulsion and the commercial product, Celebrex. DSC and XRD analyses confirmed non-crystalline CEL in SLH microcapsules and verified medium term physical stability. Dissolution under sink conditions revealed a 2- to 5-fold increase in dissolution efficiencies (%DE) and significantly reduced t(50%) (> or =50-fold) for CEL formulated as SLH microcapsules. Orally dosed in vivo studies in rats demonstrated superior pharmacokinetics for SLH microcapsules. Specifically, the fasted-state bioavailability (F) was statistically higher (p

AB - A silica-lipid hybrid (SLH) microcapsule system for oral delivery of poorly water-soluble drugs is reported for the first time. For the model drug celecoxib (CEL), SLH microcapsules composed of medium-chain triglycerides, lecithin and silica nanoparticles; with an internal porous matrix structure, were shown to offer several physicochemical and biopharmaceutical advantages in comparison with unmodified drug, lipid emulsion, dry emulsion and the commercial product, Celebrex. DSC and XRD analyses confirmed non-crystalline CEL in SLH microcapsules and verified medium term physical stability. Dissolution under sink conditions revealed a 2- to 5-fold increase in dissolution efficiencies (%DE) and significantly reduced t(50%) (> or =50-fold) for CEL formulated as SLH microcapsules. Orally dosed in vivo studies in rats demonstrated superior pharmacokinetics for SLH microcapsules. Specifically, the fasted-state bioavailability (F) was statistically higher (p

U2 - 10.1016/j.jconrel.2008.10.014

DO - 10.1016/j.jconrel.2008.10.014

M3 - Journal article

C2 - 19013488

VL - 134

SP - 62

EP - 70

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 1

ER -

ID: 40353307